TICKERNERD
Menu
MDLNHealthcare · Medical Instruments & Supplies

MDLN Stock Forecast: Medline, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$35
+2.09% on the day

The 27 Wall Street analysts covering Medline, Inc. hold a median 12-month price target of $46 — +29.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 21 of 100 as at 8 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$47.4B
Ticker Nerd rank
21 / 100
Median analyst target
$46
Analysts covering
27
Total return, dividends reinvested
1W
−10.3%
1M
−18.1%
YTD
−16.1%
From high
−29.5%
From low
+6.1%
$33
$50
Range since 17 Dec 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

MDLN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Medline, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Aug 2026
21 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
67
Revisions
64
Issuance
61
Quality
45
Value
39
Growth
32
Size
6
Momentum
2
Volatility
1

Accruals (67): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (1): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Medline, Inc. — and when they’d sell — is the membership.

Wall Street

MDLN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MDLN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Dec 2025Adjusted close, US dollars
$30$35$40$45$50$55$60$65Jan 26Apr 26Jul 26MDLNHigh $62Median $46Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says27 analysts
23 Buy4 Hold0 Sell
Low $37Median $46High $62

The green dot is the last close — the median target sits +29.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 6 moved it down.

DateFirmActionRatingTarget
6 Aug 2026Evercore ISI GroupMaintainsOutperform$48 → $39
6 Aug 2026RBC CapitalMaintainsOutperform$53 → $46
6 Aug 2026StifelMaintainsBuy$50 → $45
6 Aug 2026Truist SecuritiesMaintainsBuy$56 → $47
31 July 2026BTIGReiteratesBuy$55
3 June 2026BairdMaintainsOutperform—
3 June 2026BairdMaintainsOutperform$57 → $45
1 June 2026BarclaysMaintainsOverweight—
1 June 2026BarclaysMaintainsOverweight$50 → $45
14 May 2026BNP ParibasMaintainsNeutral—
13 May 2026Tigress FinancialMaintainsBuy—
7 May 2026BernsteinMaintainsOutperform—
7 May 2026BTIGReiteratesBuy—
7 May 2026CitigroupMaintainsBuy—
11 Mar 2026CitigroupReinstatesBuy$60
10 Mar 2026JP MorganMaintainsOverweight—
9 Mar 2026BTIGReiteratesBuy—
9 Mar 2026Tigress FinancialMaintainsBuy—
2 Mar 2026Morgan StanleyMaintainsOverweight—
27 Feb 2026Wells FargoMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

MDLN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.9%
Analysts raising
1
Analysts cutting
1
Fundamentals

Medline, Inc. (MDLN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
44.0×

Cheaper than 18% of US stocks

Price / sales
1.6×

Cheaper than 59% of US stocks

Price / book
2.7×

Cheaper than 38% of US stocks

EV / EBITDA
17.0×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
11.6%

Higher than 57% of US stocks

Earnings growth (YoY)
−82.0%

Higher than 4% of US stocks

Gross margin
28.8%

Higher than 34% of US stocks

Operating margin
5.1%

Higher than 56% of US stocks

Net margin
2.3%

Higher than 53% of US stocks

Returns & dividend
Return on equity
4.9%

Higher than 53% of US stocks

Return on assets
3.0%

Higher than 65% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

MDLN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
MDLNMedline, Inc.$47.4B
21
BDXBecton, Dickinson & Co.$48.7B
90
ALCAlcon AG$35.8B
61
RMDResMed, Inc.$30.9B
71
WSTWest Pharmaceutical Services, Inc.$25.5B
94
ISRGIntuitive Surgical, Inc.$135.8B
75
COOThe Cooper Cos., Inc.$14.5B
75
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MDLN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest MDLN news & analysis

NASDAQ: MDLN Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

PRNewsWire · 7 Aug 2026negative

Kessler Topaz Meltzer & Check, LLP announced it is investigating potential federal securities law violations by Medline Inc. on behalf of investors who purchased Class A common stock and experienced significant financial losses. The law firm is encouraging affected shareholders to contact it.

Why it matters — A securities litigation firm is investigating Medline for possible securities law violations, which could lead to legal and reputational concerns for the company and its investors.

Kaplan Fox Encourages Investors of Medline Inc. (MDLN) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

Newsfile Corp · 7 Aug 2026negative

Kaplan Fox & Kilsheimer LLP announced it is investigating potential securities violations against Medline Inc. (NASDAQ: MDLN). The firm is inviting affected investors who have suffered losses, or those with relevant information, to contact it regarding the investigation.

Why it matters — A securities investigation into the company signals possible shareholder concerns that MDLN watchers may want to monitor.

NASDAQ: MDLN Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm

Business Wire · 6 Aug 2026negative

Kessler Topaz Meltzer & Check, LLP said it is investigating potential federal securities law violations by Medline Inc. on behalf of investors who bought Medline Class A common stock and suffered significant losses. The announcement follows the FDA's June 2, 2026 publication of a warning letter to Medline dated May 28, 2026.

Why it matters — MDLN investors face possible legal exposure tied to the disclosed FDA warning letter and a law firm's securities-law investigation.

Allspring Growth Fund Q2 2026 Performance Update

Seeking Alpha · 6 Aug 2026neutral

Allspring Growth Fund outperformed the Russell 3000 Growth Index during Q2 2026, according to the fund's performance update. The report highlights Sandisk Corp. riding the AI storage super-cycle, while noting that Cencora shares could not distribute in a 'risk-on' market.

Why it matters — The update makes no mention of Medline, so its relevance to MDLN watchers is limited to general context on growth-fund performance and AI-related storage demand.

Medline Inc. (MDLN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Medline Inc. (MDLN) held its Q2 2026 earnings call, with a transcript of the event published by Seeking Alpha. The call covered the company's second-quarter financial results and discussion.

Why it matters — A MDLN watcher would care because the earnings call transcript provides direct insight into the company's quarterly performance and management commentary.

FAQ

Frequently asked questions about MDLN stock

What is the MDLN stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Medline, Inc. have a median 12-month price target of $46, with estimates ranging from $37 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MDLN stock a buy right now?

Of the 27 analysts covering Medline, Inc., 23 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medline, Inc. 21 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MDLN?

As at 8 Aug 2026, Medline, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (67 of 100).

Will MDLN stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +29.2% from the last close, and Ticker Nerd's factor model ranks Medline, Inc. 21 out of 100 as at 8 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MDLN stock forecast for 2030?

No analyst covering Medline, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MDLN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $62 over the next 12 months.

What does Medline, Inc. do?

Medline Inc. is a healthcare company that provides medical-surgical products and supply chain solutions to healthcare providers.

What is the latest news on MDLN?

The most recent item we track (PRNewsWire, 7 Aug 2026): "NASDAQ: MDLN Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm". Kessler Topaz Meltzer & Check, LLP announced it is investigating potential federal securities law violations by Medline Inc. on behalf of investors who purchased Class A common stock and experienced significant financial losses. The law firm is encouraging affected shareholders to contact it.

Company

About Medline, Inc.

Medline Inc. is a healthcare company that provides medical-surgical products and supply chain solutions to healthcare providers. The company focuses on serving hospitals, surgery centers, physician offices, laboratories, and post-acute care facilities with a broad portfolio of consumable medical products, including surgical and procedural kits, gloves and protective apparel, urological and incontinence care items, wound care products, and lab and diagnostic supplies. Medline operates through two main segments: Medline Brand, which covers the procurement and manufacture of its own med-surg product lines, and Supply Chain Solutions, which delivers logistics, distribution, and inventory management services tailored to large healthcare systems. Headquartered in Northfield, Illinois, Medline positions itself as a key partner for healthcare institutions seeking to improve clinical, operational, and financial outcomes through reliable product availability, extensive branded offerings, and integrated supply chain capabilities in the medical-surgical space.

CEO Mr. James M. Boyle · 45,000 employees · United States · https://www.medline.com